New cancer drug combo tested for safety in chinese patients
NCT ID NCT05514132
Summary
This early-stage study is testing the safety and side effects of a new two-drug combination (ceralasertib and durvalumab) in Chinese patients with advanced solid tumors. The goal is to find a safe dose for future research, as these patients' cancers have stopped responding to standard treatments. Researchers will also check how the body processes the drugs and look for any early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Beijing, 100021, China
-
Research Site
Shandong, China
Conditions
Explore the condition pages connected to this study.